Erypeg 50mcg Injection

Erypeg 50mcg Injection
Pegylated Recombinant Human Erythropoietin (50mcg)
Cheaper alternative availability
Already at the Best Price
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
About This Medicine
Product description & overview
Erypeg 50mcg Injection contains Pegylated Recombinant Human Erythropoietin, a long-acting erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease (CKD), chemotherapy, or other conditions resulting in insufficient endogenous erythropoietin production. The pegylation process extends the half-life of erythropoietin, allowing for less frequent dosing compared to non-pegylated formulations. Erypeg stimulates erythroid progenitor cells in the bone marrow, promoting red blood cell production and improving hemoglobin levels. It is indicated for the treatment of anemia in adult patients with CKD on dialysis or not on dialysis, as well as anemia due to myelosuppressive chemotherapy in non-myeloid malignancies. The injection is administered subcutaneously or intravenously under medical supervision, with dosing individualized based on patient response and hemoglobin levels. Monitoring of hemoglobin, iron status, and blood pressure is essential during therapy to avoid adverse effects such as hypertension, thromboembolic events, or pure red cell aplasia. Erypeg should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Proper patient selection and adherence to recommended dosing guidelines optimize therapeutic outcomes and minimize risks associated with erythropoiesis-stimulating agents.
Active composition
Pegylated Recombinant Human Erythropoietin 50 mcg
About Pegylated Recombinant Human Erythropoietin
Pegylated Recombinant Human Erythropoietin is an erythropoiesis-stimulating agent used to treat anemia due to chronic kidney disease and cancer. It works by stimulating red blood cell production. Pegylated Recombinant Human Erythropoietin is clinically significant for managing anemia. In summary, it is essential for improving hemoglobin levels.
How It Works
Pegylated Recombinant Human Erythropoietin: Pegylated Recombinant Human Erythropoietin binds to erythropoietin receptors in the bone marrow, stimulating erythropoiesis and increasing red blood cell production.
Dosage & How to Use
Dosage information not available. Please consult your doctor or pharmacist.
Safety Advice
Important precautions
Side Effect Occurrence
Based on clinical trials and patient reports.
Overall Tolerance
Most patients tolerate well
Common Side Effects
Safety Advice
Alcohol
Information regarding the use of Erypeg 50mcg Injection during pregnancy is not available. Please consult your doctor.
High Risk
Pregnancy
Information regarding the use of Erypeg 50mcg Injection during breastfeeding is not available. Please consult your doctor.
Medical Advice
Driving
There is limited information available on the use of Erypeg 50mcg Injection in patients with kidney disease. Please consult your doctor.
Exercise Caution
Breastfeeding
It is not known whether Erypeg 50mcg Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Kidney
There is limited information available on the use of Erypeg 50mcg Injection in patients with liver disease. Please consult your doctor.
Regular Checkup
Customer Reviews
0 reviews for Erypeg 50mcg Injection







